Last Updated: October 1, 2026

Details for Patent: 12,491,272


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,491,272 protect, and when does it expire?

Patent 12,491,272 protects LUTATHERA and is included in one NDA.

Protection for LUTATHERA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and twenty-four patent family members in twenty-five countries.

Summary for Patent: 12,491,272
Title:Stable, concentrated radionuclide complex solutions
Abstract:The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.
Inventor(s):Donato Barbato, Clementina Brambati, Daniela Chicco, Francesco de Palo, Lorenza Fugazza, Maurizio Mariani, Giovanni Tesoriere
Assignee: Advanced Accelerator Applications SA
Application Number:US18/927,058
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 12,491,272

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aaa Usa Inc LUTATHERA lutetium lu 177 dotatate SOLUTION;INTRAVENOUS 208700-001 Jan 26, 2018 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,491,272

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 119655 ⤷  Start Trial
Australia 2018433575 ⤷  Start Trial
Australia 2022203683 ⤷  Start Trial
Australia 2024201217 ⤷  Start Trial
Australia 2025202231 ⤷  Start Trial
Australia 2025204901 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.